Moreover, RCRC shows frequent and intense immune-tumor cell interactions, including through enhancement of macrophage migration by the SEMA4A-PLXND1 axis or by pro-tumorigenic signaling between immune cells (LUCAT1+ monocytes and macrophages) with the help of CD74-CD44, and possess metabolically active and highly dense CD20+ B cells correlating with favorable prognosis and shown to be essential for anti-PD-1 therapy. Here, PDCD1 is linked to neoplasm.